

Perspectives

- The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition.**
David J. McConkey and Colin P. Dinney 1001
Perspective on Seager et al., p. 1008
- Is It Time to Advance the Chemoprevention of Environmental Carcinogenesis with Microdosing Trials?** Thomas W. Kensler and John D. Groopman 1003
Perspective on Jubert et al., p. 1015

Research Articles


- Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer.** Catherine M. Seager, Anna M. Puzio-Kuter, Trushar Patel, Shalini Jain, Carlos Cordon-Cardo, James Mc Kiernan, and Cory Abate-Shen 1008
- Effects of Chlorophyll and Chlorophyllin on Low-Dose Aflatoxin B₁ Pharmacokinetics in Human Volunteers.** Carole Jubert, John Mata, Graham Bench, Roderick Dashwood, Cliff Pereira, William Tracewell, Kenneth Turteltaub, David Williams, and George Bailey 1015
- Gender Modifies the Effect of Ursodeoxycholic Acid in a Randomized Controlled Trial in Colorectal Adenoma Patients.** Patricia A. Thompson, Betsy C. Wertheim, Denise J. Roe, Erin L. Ashbeck, Elizabeth T. Jacobs, Peter Lance, María Elena Martínez, and David S. Alberts 1023
- Dietary Tricin Suppresses Inflammation-Related Colon Carcinogenesis in Male Crj: CD-1 Mice.** Takeru Oyama, Yumiko Yasui, Shigeyuki Sugie, Mamoru Koketsu, Kunitomo Watanabe, and Takuji Tanaka 1031
- EphA2 in the Early Pathogenesis and Progression of Non-Small Cell Lung Cancer.** Jennifer M. Brannan, Banibrata Sen, Babita Saigal, Ludmila Prudkin, Carmen Behrens, Luisa Solis, Wenli Dong, B. Nebiyu Bekele, Ignacio Wistuba, and Faye M. Johnson 1039
- Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice.** Karen Liby, Renee Risingsong, Darlene B. Royce, Charlotte R. Williams, Tian Ma, Mark M. Yore, and Michael B. Sporn 1050
- Preventive Effects of Bexarotene and Budesonide in a Genetically Engineered Mouse Model of Small Cell Lung Cancer.** Yian Wang, Weidong Wen, Yijun Yi, Zhongqiu Zhang, Ronald A. Lubet, and Ming You 1059
- Lack of Evidence for Green Tea Polyphenols as DNA Methylation Inhibitors in Murine Prostate.** Shannon R. Morey Kinney, Wa Zhang, Marien Pascual, John M. Grealley, Bryan M. Gillard, Ellen Karasik, Barbara A. Foster, and Adam R. Karpf 1065
- Distinct Effects of Calorie Restriction and Exercise on Mammary Gland Gene Expression in C57BL/6 Mice.** Michela Padovani, Jackie A. Lavigne, Gadisetti V.R. Chandramouli, Susan N. Perkins, J. Carl Barrett, Stephen D. Hursting, L. Michelle Bennett, and David Berrigan 1076
- The Cyclooxygenase Inhibitor Sulindac Sulfide Inhibits EP4 Expression and Suppresses the Growth of Glioblastoma Cells.** Atsushi Kambe, Hiroki Yoshioka, Hideki Kamitani, Takashi Watanabe, Seung Joon Baek, and Thomas E. Eling 1088
- A DNA Methyltransferase Inhibitor and All-trans Retinoic Acid Reduce Oral Cavity Carcinogenesis Induced by the Carcinogen 4-Nitroquinoline 1-Oxide.** Xiao-Han Tang, Martin Albert, Theresa Scognamiglio, and Lorraine J. Gudas 1100

Reviewers

- Acknowledgement to Reviewers.** 1111

About the Cover

The cover photographs illustrate the dramatic suppression of muscle-invasive bladder cancer by intravesically administered rapamycin, which inhibits the mammalian target of rapamycin (mTOR), in a genetically engineered mouse model of progression from pre-invasive to invasive bladder cancer. The larger, muscle-invasive tumor (top) developed in a mouse treated with control vehicle; the smaller, non-muscle-invasive tumor (bottom) developed in a mouse treated with rapamycin. The measures numbered along the x and y axes are centimeters. These findings are the first to demonstrate the chemopreventive effectiveness of a molecular-targeted agent given intravesically in a relevant murine bladder cancer model; they support broadening the study of intravesical therapeutic agents in high-risk non-muscle-invasive bladder cancer patients and provide a preclinical mouse model for testing novel such agents. Showing that intravesical delivery of an mTOR inhibitor blocks progression to invasive disease provides new hope for patients at a high risk for developing muscle-invasive bladder cancer, for whom few treatment options exist. See articles by Seager et al. (beginning on page 1008) and McConkey and Dinney (beginning on page 1001) for more information.



Cancer Prevention Research

2 (12)

Cancer Prev Res 2009;2:1001-1112.

| | |
|------------------------|---|
| Updated version | Access the most recent version of this article at: http://cancerpreventionresearch.aacrjournals.org/content/2/12 |
|------------------------|---|

| | |
|-----------------------------------|---|
| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org . |
| Permissions | To request permission to re-use all or part of this article, use this link http://cancerpreventionresearch.aacrjournals.org/content/2/12 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. |